Evaluating skin symptoms in dermatomyositis patients
Official title: Evaluation of Clinical Responsiveness Using the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI)
Run by University of Pennsylvania · NCT02945345 · Data updated 2026-11-12
This study is trying to see how skin symptoms affect people with dermatomyositis and how they respond to treatment using a special scoring system.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 300 (estimated) |
| Sponsor | University of Pennsylvania Academic / other |
| Locations | 1 site (Philadelphia, Pennsylvania) |
| Status | Recruiting |
| Started | June 2008 |
| Main results expected | January 2, 2030 |
| Study ends | January 2, 2030 |
| Registry record updated | March 30, 2026 |
| Trial ID | NCT02945345 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are adults over 18 years old diagnosed with cutaneous dermatomyositis.
✕Probably not a fit
Patients without cutaneous dermatomyositis or those who are cognitively impaired may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational study focuses on assessing the clinical responsiveness of patients with dermatomyositis using the Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI). Conducted at the University of Pennsylvania, it utilizes a comprehensive database that collects valuable information on disease processes, psychological responses, treatments, and quality of life. The CDASI serves as a validated outcome measure to evaluate the clinical course and impact of dermatomyositis on patients' lives. The ongoing nature of this database allows for continuous insights into the condition and its management.
Why it matters
Potential benefit: If successful, this study could enhance understanding of dermatomyositis and improve treatment strategies, ultimately leading to better patient outcomes.
How similar studies have gone: Other studies utilizing similar assessment tools have shown promise in improving understanding and management of dermatomyositis, indicating a potential for success in this approach.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Gender/Age: Males or females above 18 years old * Diagnosis: Cutaneous Dermatomyositis * Subjects able to give informed consent Exclusion Criteria: * Subjects without cutaneous DM * Penn employees * Penn students * Cognitively impaired persons
Where it's running
-
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania, United States Recruiting
Study contacts
- Study coordinator: Victoria Werth, MD
- Email: werth@pennmedicine.upenn.edu
- Phone: 215-615-2940
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Anti-CD19/BCMA universal CAR-T cell therapy for refractory autoimmune diseases
This will try anti-CD19/BCMA universal CAR-T cell therapy in adults with refractory rheumatoid arthritis, dermatomyositis, systemic lupus, or systemic sclerosis to see if it is safe and can control their disease.
-
Emapalumab for MDA5-positive RP-ILD in adults
This study tests whether emapalumab can help adults with anti-MDA5 positive rapidly progressive interstitial lung disease who have dermatomyositis-related conditions.
-
Long-term follow-up after KYV-101 (CAR T) treatment
This follow-up will test how long KYV-101 CAR T cells persist and record any delayed side effects in people who previously received KYV-101 for autoimmune diseases like lupus nephritis, myasthenia gravis, stiff person syndrome, rheumatoid arthritis, or multiple sclerosis.
-
Tocilizumab treatment for anti-MDA5 positive dermatomyositis in adults
This study will try giving tocilizumab or a placebo to adults with anti-MDA5 positive dermatomyositis to see if it improves symptoms and breathing.
-
Patient-rooted insights to shape myositis science
This global project asks people living with myositis (and their care partners) to share experiences and rank research questions so the community can see which issues matter most.
-
Panniculitis linked to dermatomyositis
This research will see if people with dermatomyositis who develop panniculitis have distinct clinical or tissue (histologic) features compared with panniculitis from other causes.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.